Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
Fosaprepitant dimeglumine
Medication labelFosaprepitant for injection, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and…
Why this: Advisory · dailymed-prescription
Fosaprepitant for injection, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: • acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. • delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). Limitations of Use • Fosaprepitant for injection has not been studied for the treatment of established nausea and vomiting.
- generic_name
- fosaprepitant dimeglumine
- product_names
- Fosaprepitant dimeglumine
- ndc
- 68001-523, 68001-523-36
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en